Eletrobras Q2 Results: Adjusted Net Income Rises to R$1.469 Million, Net Operating Revenue Down 0.3% Y/Y

Centrais Elétricas Brasileiras S.A. (Eletrobrás) reported Q2 adjusted net income of R$1,469 million and regulatory net operating revenue of R$9,593 million, a decrease of 0.3% year-over-year. Eletrobrás is a Brazilian electric utility company listed on the New York Stock Exchange under the ticker symbol EBR.

Knight Therapeutics Inc. (KTH) reported its Q2 2025 financial results, showcasing a 12% year-over-year (YoY) revenue increase, which exceeded analyst expectations. The company's Q2 revenue stood at C$107.36 million, surpassing the consensus estimate of C$95.70 million [1].

Despite the revenue growth, Knight Therapeutics reported a net loss of C$12.62 million for the quarter, primarily due to hyperinflation in Argentina, increased operating expenses, and financial asset revaluation losses. The company's gross margin declined, influenced by hyperinflation accounting and product mix changes.

Knight Therapeutics completed the acquisition of Paladin and secured a $50 million credit facility with NBC. The company also raised its 2025 revenue guidance to C$410 million to C$420 million, driven by strong H1 performance and the Sumitomo transaction. Adjusted EBITDA is expected to be 13% of 2025 revenues, assuming no major supply disruptions or new generic competition.

Analysts remain bullish on Knight Therapeutics, with an average rating of "buy" and a Wall Street median 12-month price target of C$7.50, about 16.1% above its August 6 closing price of C$6.29. The stock recently traded at 73 times the next 12-month earnings compared to a P/E of 93 three months ago.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXC4244C:0-knight-therapeutics-q2-revenue-beats-expectations/